ARTICLE | Company News
Amgen sales and marketing update
January 25, 2016 8:00 AM UTC
The French National Authority for Health (HAS) recommended that Repatha evolocumab from Amgen be covered by the public health insurance only as a last-resort treatment in patients with familial homozygous hypercholesterolemia. Only about 100 patients will be eligible for the drug. ...